Furthermore, before performing US tests, patients were asked to self-assess their approach to testing, with special attention to their mood (i.e. anxiety, mistrust), and also to its usefulness according to a VAS (Visive Analogic Scale) score ranging from 0 (excessive or inadequate) to 100 (very useful).

These data were included in the form. Finally, given the limitations associated with the frequent need for long-term planning of investigations, in relation to planned follow-up visits, we calculated the time interval between the date of request and the date on which it was actually performed. About 10% of US Luminespib research buy requests examined were excluded from the study for incomplete clinical and instrumental data obtained. Statistical methodology All results were reported with frequencies and medians; the associations were estimated using the Chi-squared test or Fisher’s Exact, when appropriate. The comparison between the Cytoskeletal Signaling inhibitor two groups of interest was evaluated using the Mann–Whitney test. All the analyses were performed utilizing SPSS statistical software. (SPSS, Chicago, Il, U.S.A.; Version 20.0). Results The final study population was composed of 546 patients, respectively 277 MK0683 mouse females (50.7%) and 269 males (49.3%). The length of follow-up of these patients was 37 months

(median time), with a mean of 2.3 tests performed per individual patient. A total number of 1240 US tests were performed over four months. The cost of these exams, borne by the national health care system, amounted to 41,882 Euros. Out of 1240, 378 requests (30.5%) were inappropriate. Results related to tumor localization and final study population characteristics are extensively reported in Tables 1, 2. Table 1 Results related to the Docetaxel purchase melanoma, the requests and the US examinations

in Patient Group A (melanoma thickness > 1 mm) and Group B (< 1 mm) Results Group A n =290 Group B n =256 N (%) N (%) Site of melanomas 18 (6.2) 8 (3.1)    Head-neck 138 (47.6) 116 (45.3)    Upper torso 32 (11.0) 30 (11.7)    Lower torso 30 (10.3) 38 (14.8)    Upper Limbs 72 (24.8) 64 (25.0)    Lower Limbs     Sentinel Lymph node 228 (82.0) 2 (0.8) Ulceration 20 (6.97) 0 (0) Regression 2 (0.7) 2 (10.8) Multiple melanoma 40 (13.8) 0 (0) Familiarity 4 (1.4) 0 (0) Mitosis 10 (3.4) 0 (0) Urgent requests 16 (65.5) 4 (1.6) Total US tests 644 596 Total unjustified US tests 206 (32.0)* 172 (28.9)* Total cost (Euros) 21902.8 19979.6 Unjustified cost (Euros) 6709.4 (30.6)** 5704 (28.5)** Note. * Out of total tests ** Out of total cost. Table 2 Characteristics of the final study population (n = 546) split into two groups [Group A (melanoma thickness > 1 mm) and Group B (< 1 mm)] Characteristics Group A n = 290 Group B n = 256 P value Sex n(%) n(%) 0.88    M 148 (51.0) 129 (50.4)      F 142 (49.0) 127 (49.